194 related articles for article (PubMed ID: 25437128)
21. Vancomycin pharmacodynamics and survival in patients with methicillin-resistant Staphylococcus aureus-associated septic shock.
Zelenitsky S; Rubinstein E; Ariano R; Iacovides H; Dodek P; Mirzanejad Y; Kumar A;
Int J Antimicrob Agents; 2013 Mar; 41(3):255-60. PubMed ID: 23312606
[TBL] [Abstract][Full Text] [Related]
22. Predictors of mortality for methicillin-resistant Staphylococcus aureus health-care-associated pneumonia: specific evaluation of vancomycin pharmacokinetic indices.
Jeffres MN; Isakow W; Doherty JA; McKinnon PS; Ritchie DJ; Micek ST; Kollef MH
Chest; 2006 Oct; 130(4):947-55. PubMed ID: 17035423
[TBL] [Abstract][Full Text] [Related]
23. Simple approach to improving vancomycin dosing in intensive care: a standardised loading dose results in earlier therapeutic levels.
Truong J; Levkovich BJ; Padiglione AA
Intern Med J; 2012 Jan; 42(1):23-9. PubMed ID: 22276559
[TBL] [Abstract][Full Text] [Related]
24. Monitoring of vancomycin serum levels for the treatment of staphylococcal infections.
Kitzis MD; Goldstein FW
Clin Microbiol Infect; 2006 Jan; 12(1):92-5. PubMed ID: 16460555
[TBL] [Abstract][Full Text] [Related]
25. Relationships between vancomycin minimum inhibitory concentration, dosing strategies, and outcomes in methicillin-resistant Staphylococcus aureus bacteremia.
Clemens EC; Chan JD; Lynch JB; Dellit TH
Diagn Microbiol Infect Dis; 2011 Dec; 71(4):408-14. PubMed ID: 21924852
[TBL] [Abstract][Full Text] [Related]
26. Assessment of Appropriateness of an Initial Dosing Regimen of Vancomycin and Development of a New Dosing Nomogram.
Yoon S; Park KR; Lee S; Song SH; Park WB; Jang IJ; Yu KS
Basic Clin Pharmacol Toxicol; 2018 Feb; 122(2):233-238. PubMed ID: 28834212
[TBL] [Abstract][Full Text] [Related]
27. Assessment of vancomycin dosing and subsequent serum concentrations in pediatric patients.
Eiland LS; English TM; Eiland EH
Ann Pharmacother; 2011 May; 45(5):582-9. PubMed ID: 21521865
[TBL] [Abstract][Full Text] [Related]
28. The pharmacokinetics and pharmacodynamics of vancomycin in clinical practice: evidence and uncertainties.
Vandecasteele SJ; De Vriese AS; Tacconelli E
J Antimicrob Chemother; 2013 Apr; 68(4):743-8. PubMed ID: 23249839
[TBL] [Abstract][Full Text] [Related]
29. Evaluation of a vancomycin dosing nomogram in achieving high target trough concentrations in Taiwanese patients.
Leu WJ; Liu YC; Wang HW; Chien HY; Liu HP; Lin YM
Int J Infect Dis; 2012 Nov; 16(11):e804-10. PubMed ID: 22917921
[TBL] [Abstract][Full Text] [Related]
30. Vancomycin dosing for pneumonia in critically ill trauma patients.
Patanwala AE; Norris CJ; Nix DE; Kopp BJ; Erstad BL
J Trauma; 2009 Oct; 67(4):802-4. PubMed ID: 19820588
[TBL] [Abstract][Full Text] [Related]
31. An evaluation of vancomycin dosing for complicated infections in pediatric patients.
Durham SH; Simmons ML; Mulherin DW; Foland JA
Hosp Pediatr; 2015 May; 5(5):276-81. PubMed ID: 25934812
[TBL] [Abstract][Full Text] [Related]
32. The pharmacokinetic/pharmacodynamic rationale for administering vancomycin via continuous infusion.
Waineo MF; Kuhn TC; Brown DL
J Clin Pharm Ther; 2015 Jun; 40(3):259-65. PubMed ID: 25865426
[TBL] [Abstract][Full Text] [Related]
33. Pharmacokinetics of vancomycin in extremely obese patients with suspected or confirmed Staphylococcus aureus infections.
Adane ED; Herald M; Koura F
Pharmacotherapy; 2015 Feb; 35(2):127-39. PubMed ID: 25644478
[TBL] [Abstract][Full Text] [Related]
34. Vancomycin: we can't get there from here.
Patel N; Pai MP; Rodvold KA; Lomaestro B; Drusano GL; Lodise TP
Clin Infect Dis; 2011 Apr; 52(8):969-74. PubMed ID: 21460308
[TBL] [Abstract][Full Text] [Related]
35. Vancomycin dosing and monitoring 2 years after the guidelines.
Lomaestro BM
Expert Rev Anti Infect Ther; 2011 Jun; 9(6):657-67. PubMed ID: 21692671
[TBL] [Abstract][Full Text] [Related]
36. Evolution of empiric vancomycin dosing in a neonatal population.
Radu L; Bengry T; Akierman A; Alshaikh B; Yusuf K; Dersch-Mills D
J Perinatol; 2018 Dec; 38(12):1702-1707. PubMed ID: 30341404
[TBL] [Abstract][Full Text] [Related]
37. A stewardship program's retrospective evaluation of vancomycin AUC24/MIC and time to microbiological clearance in patients with methicillin-resistant Staphylococcus aureus bacteremia and osteomyelitis.
Gawronski KM; Goff DA; Brown J; Khadem TM; Bauer KA
Clin Ther; 2013 Jun; 35(6):772-9. PubMed ID: 23795575
[TBL] [Abstract][Full Text] [Related]
38. Impact of pharmacist intervention on preventing nephrotoxicity from vancomycin.
Masuda N; Maiguma T; Komoto A; Haruki Y; Sugiyama T; Kondo S; Teshima D
Int J Clin Pharmacol Ther; 2015 Apr; 53(4):284-91. PubMed ID: 25740266
[TBL] [Abstract][Full Text] [Related]
39. Comparison of bactericidal activities of intermittent and continuous infusion dosing of vancomycin against methicillin-resistant Staphylococcus aureus and Enterococcus faecalis.
Klepser ME; Patel KB; Nicolau DP; Quintiliani R; Nightingale CH
Pharmacotherapy; 1998; 18(5):1069-74. PubMed ID: 9758317
[TBL] [Abstract][Full Text] [Related]
40. Supratherapeutic vancomycin levels after trauma predict acute kidney injury and mortality.
Ley EJ; Liou DZ; Singer MB; Mirocha J; Srour M; Bukur M; Margulies DR; Salim A
J Surg Res; 2013 Sep; 184(1):501-6. PubMed ID: 23731689
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
